L. P. Collins

A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

I. Pavord, A. Chuchalin, J. Bell, 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

The Potent and Selective CRTH2 Antagonist OC000459 Is Effective In The Treatment Of Eosinophilic Asthma When Given Once Daily

J. Bell, R. Pettipher, M. Payton, 2014 .

Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459

J. Bell, R. Pettipher, M. Payton, 2014, Allergy.

856 Treatment of Eosinophilic Esophagitis With the CRTH2-Antagonist Oc000459: A Novel Therapeutic Principle

A. Straumann, H. Simon, C. Bussmann, 2012 .

The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial

F. Horak, P. Lemell, R. Zieglmayer, 2012, Allergy.

Anti‐eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis

A. Straumann, H. Simon, C. Bussmann, 2013, Allergy.

The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial

P. Lemell, R. Zieglmayer, P. Zieglmayer, 2012, Allergy.

Anti‐eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis

A. Straumann, H. Simon, C. Bussmann, 2013, Allergy.

P.048 Results of the predict randomised controlled trial: clinical effects of using the predict test to guide antidepressant treatment in depression

G. Dawson, G. Goodwin, V. Pérez, 2019, European Neuropsychopharmacology.